- 2024.08.26
Press Releases
2024.08.28
Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific) Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific) Well-positioned for […]
2024.08.26
ROCKVILLE, MD, August 26, 2024 – I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. H.C. Wainwright 26th Annual Global Investment Conference […]
2024.08.07
Engagement is part of I-Mab’s commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, MD, August 7, 2024 – I-Mab (NASDAQ: IMAB) (“I-Mab”, the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the […]
I-Mab was established in June 2016
I-Mab completed Series A financing, raising $58 million
Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing
I-Mab successfully raised $227 million in Series C Financing
I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company
I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab
I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium
I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou
I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China
I-Mab signed agreement to divest its assets and business operations in China, bringing a greater focus on the U.S. and ex-China markets